Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aristotle University Of Thessaloniki
Age
21–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Open-angle glaucoma patients (primary open-angle glaucoma, exfoliative, or pigmentary glaucoma) insufficiently controlled on branded, or generic latanoprost monotherapy (IOP \> 20 mm Hg as determined by 2 separate IOP measurements at 10:00 ± 1 hour)
Patients with signs, or symptoms of ocular surface disease.
Only those open-angle glaucoma subjects who, according to the opinion of the principal investigator, require further IOP reduction.
Patients must have demonstrated at least 20% IOP reduction at 10:00 (± 1 hour) and who are treated with branded, or generic latanoprost monotherapy for at least 3 months.
Only subjects with open-angle glaucoma that have exhibited (prior to latanoprost therapy) untreated, sitting IOP evaluated with Goldmann tonometry between 25-39 mm Hg at 10:00 (± 1 hour).
Age between 21-85 years
Mild to moderate glaucomatous disc damage and visual field loss (less than -12 dB mean deviation visual field loss attributed to glaucoma
Those with 0.8 or better vertical cup-to-disc ratio and visual acuity greater than 0.1 in the study eye.
Open anterior chamber angles.
Those who have to demonstrate a reliable visual field (at least two visual fields with less than 20% fixation losses, false positives, or negatives)
Patients who understand study instructions, are willing to attend all follow-up appointments and will comply with study medication usage.
You may not be if
Patients with a history of less than 10% IOP decrease on any IOP-lowering medication.
Those with evidence of concurrent conjunctivitis, keratitis, or uveitis in either eye.
Subjects with a history of inadequate adherence; intolerance, or contraindication to either prostaglandins, β-blockers, dorzolamide, or benzalconium chloride (BAK)
Patients with severe ocular surface disease, previous intraocular conventional or laser surgery in the study eye (within 6 months prior to enrolment); previous history of ocular trauma; use of corticosteroids (within 3 months before the enrolment) and use of contact lenses.
Those that on baseline examination show clinical evidence of inflammation, signs of ocular infection (except blepharitis), signs of any corneal abnormality that will affect subsequent IOP measurements
Subjects that show unwillingness to participate in the trial.
Females of childbearing potential or lactating mothers.
Clareo Health | 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy
